ZFIN ID: ZDB-PUB-101011-15
The zebrafish embryo as a model for assessing off-target drug effects
Strähle, U., and Grabher, C.
Date: 2010
Source: Disease models & mechanisms   3(11-12): 689-692 (Review)
Registered Authors: Grabher, Clemens, Strähle, Uwe
Keywords: none
MeSH Terms:
  • Animals
  • Benzothiazoles/pharmacology
  • Cholinesterase Inhibitors/pharmacology
  • DNA-Binding Proteins/antagonists & inhibitors
  • DNA-Binding Proteins/metabolism
  • Drug-Related Side Effects and Adverse Reactions*
  • Embryo, Nonmammalian/drug effects*
  • Humans
  • Models, Animal*
  • Nuclear Proteins/antagonists & inhibitors
  • Nuclear Proteins/metabolism
  • Pyrazoles/pharmacology
  • Pyrimidines/pharmacology
  • Toluene/analogs & derivatives
  • Toluene/pharmacology
  • Tumor Suppressor Protein p53/antagonists & inhibitors
  • Tumor Suppressor Protein p53/metabolism
  • Tumor Suppressor Proteins/antagonists & inhibitors
  • Tumor Suppressor Proteins/metabolism
  • Zebrafish/embryology*
PubMed: 20876356 Full text @ Dis. Model. Mech.
Although first used experimentally for the genetic analysis of vertebrate development and neurobiology, the zebrafish has been adapted as a model for many human diseases. In recent years, the zebrafish embryo has increasingly attracted the attention of chemists and pharmacologists for its utility in identifying chemicals with pharmacological activity in a whole-animal context. Its experimental virtues make it an ideal system with which to identify new bioactive molecules, and to assess their toxicity and teratogenicity at medium-to-high throughput. More recently, the zebrafish embryo has been applied to identify off-target effects of drug candidates. Here, we discuss the value of the zebrafish embryo for detecting off-target effects, and propose that this model could be useful for improving the efficiency of the drug-development pipeline.